Incyte (NASDAQ:INCY) and Novartis AG (NYSE:NVS) reached a settlement regarding royalty payments in an existing collaboration ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

Incyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets. While Incyte markets Jakafi in the United States, Novartis markets the same ...

Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against COVID-19, after it failed to cut complications or death in a phase 3 trial.

The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis ...

Incyte and Morphosys’ Monjuvi antibody therapy ... for acute lymphoblastic leukaemia (ALL), as well as two CAR-T therapies – Novartis’ Kymriah (tisagenlecleucel) and Gilead’s Yescarta ...

A Delaware district court must maintain its pause of an order that the FDA delay final approval of MSN Laboratories Pvt. Ltd.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know. Incyte beat analysts’ revenue expectations by 3% last ...

Incyte Corporation INCY is expected to beat estimates when it reports first-quarter 2025 earnings results on April 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported ...